In this study we provide the molecular mechanisms mediating the previously observed atherogenic properties of p66(Shc). Taken together, our data set the stage for the design of novel therapeutic tools to retard atherogenesis through the inhibition of p66(Shc).
2011-08-18
Eng.
Arteriosclerosis, thrombosis, and vascular biology
Cardiovascular Research, Institute of Physiology, University of Zürich, Zürich, Switzerland.
Arterioscler Thromb Vasc Biol. 2011 Sep;31(9):2090-7
© Galenicom 1999-2013